Marijuana stocks may seem a tempting investment, but make sure you're aware of the associated risks before diving into this burgeoning market. Many, or all, of the products featured on this page ...

Cannabis stocks jumped after the U.S. Department of Health and Human Services recommended easing restrictions on marijuana in August. However, cannabis also has seen slower-than-forecast progress ...

Cannabis-related ETFs continued to gain in the premarket on Thursday after President-elect Donald Trump nominated Matt Gaetz, a Republican Congressman seen as a long-time advocate for marijuana ...

The Horizons Marijuana Life Sciences Index ETF ... told Insider that while Stifel doesn't label any of the stocks it covers as "top picks," he would highlight Weedmaps as a company that has ...

However, possessing or selling marijuana remains a crime under federal ... that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter ...

That means these marijuana stocks are primed to move ... as a single company with blockbuster returns. Whether you pick individual stocks, ETFs or a mix of both, remember that Biden's announcement ...

Marijuana ETFs offer diversification, lowering risk versus individual stocks. AdvisorShares Pure U.S. Cannabis ETF is the largest marijuana ETF and heavily invests in major U.S. cannabis companies.

The reclassification of marijuana as a Schedule 3 drug and passage of the Safe Banking Act could ignite another big cannabis stock rally. The reclassification of marijuana as a Schedule 3 drug and ...

Cannabis stocks are a part of an emerging market of legalized marijuana, which involves the harvesting, packaging, and retail sale of good old Mary Jane. In Canada, the cannabis industry has ...

Shares of U.S. and Canadian cannabis companies retreated after a Drug Enforcement Administration judge postponed hearings on whether to reschedule marijuana to a less-dangerous drug category.

Shares of cannabis stocks slumped after a company set to testify in the Drug Enforcement Administration's rescheduling hearings accused the agency of obstructing the rulemaking process ...